Parvovirus B19

Parvovirus B19, Parvoviridae familyasının Erytrovirus genusunda yer alan küçük bir DNA virusudur. Virusun yaklaşık olarak %13- 14 oranında farklı nükleotid sekansa sahip üç genotipi tanımlanmıştır. Genotip 3 sahra-altı Afrika ve Güney Amerika ile sınırlı iken genotip 1 ve 2, Avrupa ve ABD'de yaygındır. Parvovirus B19, solunum yolu sekresyonları başta olmak üzere kan transfüzyonu, organ nakli ve transplasental yol ile bulaşmaktadır. Çocukluk çağının döküntülü hastalıklarından eritema infeksiyozumun etkeni olan par- vovirus B19, erişkinlerde artropatilere, özellikle kronik hemolitik anemisi olan hastalarda aplastik krize neden olmaktadır. Hamile bir kadının B19 virusu ile enfekte olması sonucunda, fetüste hidrops fetalis ve konjenital anemi gelişebilmektedir. Enfeksiyonun özgül etiyolojik tanısı serolojik testlerle ve polimeraz zincir reaksiyonu yöntemi kullanılarak viral nükleik asidin belirlenmesi ile yapılabilir. Klinik çalışmalarla güvenli ve etkili olduğu gösterilen aşı adayları olmasına rağmen hiçbiri kullanım için onaylanmamıştır. Virusa özgül antiviral tedavi yoktur, semptomatik tedavi uygulanmaktadır

Parvovirus B19

Parvovirus B19 is a small DNA virus belongs to Erytrovirus genus of Parvoviridae family. Three genotypes of the virus which have approximately 13-14% nucleotide sequence differences are defined. Genotype 1 and 2 are common in Europe and the United States while genotype 3 is limited to sub-Saharan Africa and South America. Parvovirus B19 is transmitted by mainly respiratory tract sec- retions, blood transfusion, organ transplantation and transplacental route. Parvovirus B19, a causative agent of erythema infectiosum which is an eruptive diseases of childhood, causes arthropathies in adults, aplastic crisis especially in patients with chronic hemolytic anemia. Hydrops fetalis and congenital anemia may develop in a fetus as a concequence of an infection in a pregnant woman with B19 virus. Spesific etiologic diagnosis of infection can be made by serological tests or detection of viral nucleic acid by polymerase chain reaction. Although there are vaccine candiadates shown to be safe and efficacious in clinical trials, none of them is approved currently for use. There is no specific antiviral therapy, the treatment is symptomatic

PDF

___

Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like partic- les in human sera. Lancet 1975;1:72-3.
Allander T, Tammi MT, Eriksson M, et al. Cloning of a human par- vovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005;102:12891-6.
Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses iden- tified in patients with acute viral infection syndrome. J Virol 2005;79:8230-6.
Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovi- rus, the cause of erythema infectiosum (fifth disease)? Lancet 1983;1:1378.
White DG, Woolf AD, Mortimer PP, et al. Human parvovirus arth- ropathy. Lancet 1985;1:419-21.
Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981;1:664-5.
Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infec- tion associated with hydrops fetalis. Lancet 1984;2:1033-4.
Anderson LJ. Human Parvovirus B19. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 2th ed. Washington: ASM Press 2002;28:597-607.
Sharp CP, LeBreton M, Kantola K, et al. Widespread infection with homologues of human parvoviruses B19, PARV4, and hu- man bocavirus of chimpanzees and gorillas in the wild. J Virol 2010;84:10289-96.
Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th ed. Philadelphia: Elsevier Mosby:2005;56:573-7.
Portmore AC. Parvoviruses (erythema infectiosum, aplastic crisis). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone 1995:1439-46.
White DO, Fener FJ. Parvoviridae. Medikal Viroloji. (Çeviri: Doy- maz MZ) İstanbul: Nobel Tıp Kitabevleri 2000;17:285-93.
Jones LP, Erdman DD, Anderson LJ. Prevalence of antibodies to human Parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 1999;180:500-4.
Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvovi- ral infection in humans. J Infect Dis 1985;152:257-65.
Jordan JA. Human Parvoviruses. In: Murray PR, Baron EJ, Jorgen- sen JH, Landry ML, Pfaller MA editors. Manual of Clinical Micro- biology. 9th ed. (Çeviri ed: Başustaoğlu A) Ankara: Atlas Kitapçılık 2009:1622-30.
Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reproduc Toxicol 2006;21:421-35.
Barlaw GD, McKendrick MW. Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 2000;40:192-5.
Wan Z, Zhi N, Wong S, Keyvanfar K, et al. Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via dere- gulation of the E2F family of transcription factors. J Clin Invest 2010;120(10):3530-44.
Chen AY, Zhang EY, Guan W, et al. The small 11 kDa nonstructu- ral protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progeni- tor cells. Blood 2010;115:1070-80.
Sütçüoğlu S, Köse Ş, Çokçeken Okçu S, Avcı M. Parvovirus B19 İnfeksiyonu. İnfeks Derg 2001;15:391-6.
Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus atrhropathy outbreak in southwestern United states. J Rheumatol 2000;27:2444-8.
Gilbert NL, Gyorkos TW, Beliveau C, et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol Infect 2005;133:299-304.
Honda K, Ishiko O, Tsujimura A, et al. Neutropenia accompanying parvovirus B19 infection after gynecologie surgery. Acta Haematol 2000;103:186-90.
Cherry JD. Parvoviruses. In: Feigin RD, Cherry DJ, editors. Text- book of Pediatric Infectious Diseases. 4th ed. Philadelphia: W. B. Saunders Company 1998; 158:1620-7.
Doğru Ü. Eritema İnfeksiyozum. In: Topçu AW, Söyletir G, Doğa- nay M, editörs. İnfeksiyon Hastalıkları. İstanbul: Nobel Tıp Kita- bevleri 1996;85:734-7.
Aydinoz S, Karademir F, Suleymanoglu S, et al. Parvovirus B19 associated papular-purpuric gloves-and-socks syndrome. Turk J Pediatr 2006;48:351-3.
Naides SJ. Parvoviruses. In: Cohen J, Powderly WG editors. Infecti- ous Diseases. 2nd ed.Toronto: Mosby 2004;127:2049-51.
Barash J, Dushnitzky D, Sthoeger D, et al. Human parvovirus B19 infection in children: uncommon clinical presentations. Isr Med Assoc J 2002;4:763-5.
Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003;70:6-11.
Wilding J, Michon P, Siba P, et al. Parvovirus B19 infection cont- ributes to severe anemia in young children in papua new guinea. J Infect Dis 2006;194:146-53.
Özsan Murat. Parvoviruslar. In: Topçu AW, Söyletir G, Doğanay M, editörs. İnfeksiyon Hastalıkları ve Mikrobiyolojisi. İstanbul: Nobel Tıp Kitabevleri 2002;121:1217-24.
Levinson W. Parvoviruslar. Tıbbi Mikrobiyoloji ve İmmunoloji. 8nd ed. (Çeviri: Özgünen T) Ankara: Güneş Kitabevi 2006;293-4.
Koch WC. Parvovirus B19. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson Textbook of Pediatrics. 16th ed. Philadelphia: W.B. Saunders Company 2000;244 :964-6.
Young NS, Brown KE. Mechanisms of disease Parvovirus B19. N Engl J Med 2004;350:586-97.
Goff M. Parvovirus B19 in pregnancy. J Midwifery Womens Health 2005; 50:536-8.
Bonvicini F, Puccetti C, Salfi NC, et al. Gestational and fetal out- comes in B19 maternal infection: a problem of diagnosis. J Clin Microbiol 2011;49:3514-8.
Plachouras N, Stefanidis K, Andronikou S, et al. Severe nonimmu- ne hydrops fetalis and congenital corneal opacification secondary to human parvovirus B19 infection. A case report. J Reprod Med 1999;44:377-80.
Kirchner JT. Erythema infectiosum and other parvovirus B 19 infe- ctions. Am Fam Physician 1994;50:335-41.
Işık N, Ağaçfidan A. İnsan Parvovirus B19 infeksiyonlarının tanı- sında kullanılan moleküler biyoloji yöntemleri. Türk Mikrobiyol Cem Derg 2003;33:377-80
Kurtoğlu E, Tunç R. Allogeneik kök hücre nakli sonrası gelişen parvovirus B19'un neden olduğu geçici aplastik kriz olgusu. Genel Tıp Derg 2002;4:155-57.
Al-Khan A, Caligiuri A, Apuzzio J. Parvovirus B19 infection du- ring pregnancy. Infect Dis Obstet Gynecol 2003;11:175-9.
Koenigbauer F, Eastlund T, John W. Clinical illness due to Parvovi- rus B19 infection after injection of solvent/ detergent treated poo- led plasma. Transfusion 2000;40:1203-6.
Jiang W, Baker HJ, Swango LJ, et al. Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. Vaccine 1998;16:601-7.
Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003;187:675-8.
Bernstein DI, El Sahly HM, Keitel WA, et al. Safety and im- munogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011;29:7357-63.